Skip to main content

Table 2 Serological HPV 6,11,16,18 and 45 genotype-specific outcomes* and Any-HPV detection in the oral samples at the follow-up visits

From: Outcomes of HPV type-specific serostatus do not associate with oral or genital HPV-carriage in non-vaccinated women followed for three years

  

Baseline

2 months

6 months

12 months

24 months

36 months

HPV type

Serological outcome

HPV + n (%)

HPV − n (%)

HPV + n (%)

HPV − n (%)

HPV + n (%)

HPV − n (%)

HPV + n (%)

HPV − n (%)

HPV + n (%)

HPV − n (%)

HPV + n (%)

HPV − n (%)

 

Always Seronegative

12(32.4)

56 (29.6)

17(34.7)

51 (29.5)

16(30.2)

51 (30.2)

12(27.3)

56 (30.6)

14(27.5)

51 (32.7)

10(31.3)

53 (31.0)

HPV6

Seroconversion

1 (2.7)

4 (2.1)

0 (0.0)

5 (2.9)

1 (1.9)

4 (2.4)

1 (2.3)

4 (2.2)

1 (2.0)

3 (1.9)

0 (0.0)

3 (1.8)

 

Persistent Seropositivity

24(64.9)

129 (68.3)

32 (65.3)

117 (67.6)

36 (67.9)

114 (67.5)

31 (70.5)

123 (67.2)

36 (70.6)

102 (65.4)

22 (68.8)

115 (67.3)

 

Always Seronegative

28 (80.0)

158 (81.4)

39(83.0)

146 (81.6)

46 (85.2)

137 (80.1)

33 (80.5)

153 (81.4)

42 (89.4)

137 (83.0)

26 (81.3)

148 (84.1)

HPV11

Seroconversion

2 (5.7)

2 (1.0)

3 (6.4)

1 (0.6)

1 (1.9)

3 (1.8)

1 (2.4)

3 (1.6)

1 (2.1)

0 (0.0)

0 (0.0)

2 (1.1)

 

Persistent Seropositivity

5 (14.3)

34 (17.5)

5 (10.6)

32(17.9)

7 (13.0)

31 (18.1)

7 (17.1)

32 (17.0)

4 (8.5)

28 (17.0)

6 (18.8)

26 (14.8)

 

Always Seronegative

26 (70.3)

122 (64.6)

30 (62.5)

116 (66.7)

28 (62.2)

117 (66.1)

24 (58.5)

124 (68.9)

26 (59.1)

115 (70.1)

19 (59.4)

118 (69.0)

HPV16

Seroconversion

1 (2.7)

11 (5.8)

2 (4.2)

9 (5.2)

2 (4.4)

10 (5.6)

2 (4.9)

10 (5.6)

3 (6.8)

6 (3.7)

1 (3.1)

9 (5.3)

 

Persistent Seropositivity

10 (27.0)

56 (29.6)

16 (33.3)

49 (28.2)

15 (33.3)

50 (28.2)

15 (36.6)

51 (28.3)

15 (34.1)

43 (26.2)

12 (37.5)

44 (25.7)

 

Always Seronegative

33 (78.6)

155 (74.5)

42 (79.2)

144 (75.0)

46 (79.3)

140 (74.5)

33 (80.5)

156 (74.3)

41 (75.9)

137 (77.0)

29 (80.6)

144 (75.0)

HPV18

Seroconversion

3 (7.1)

8 (3.8)

2 (3.8)

8 (4.2)

1 (1.7)

10 (5.3)

0 (0.0)

11 (5.2)

3 (5.6)

8 (4.5)

0 (0.0)

11 (5.7)

 

Persistent Seropositivity

6 (14.3)

45 (21.6)

9 (17.0)

4 (20.8)

11 (19.0)

38 (20.2)

8 (19.5)

43 (20.5)

10 (18.5)

33 (18.5)

7 (19.4)

37 (19.3)

 

Always Seronegative

42 (93.3)

199 (90.5)

53 (93.0)

184 (90.6)

58 (89.2)

181 (91.9)

47 (92.2)

195 (90.7)

55 (93.2)

173 (92.0)

35 (89.7)

187 (92.1)

HPV45

Seroconversion

1 (2.2)

3 (1.4)

1 (1.8)

3 (1.5)

2 (3.1)

2 (1.0)

2 (3.9)

2 (0.9)

2 (3.4)

1 (0.5)

1 (2.6)

2 (1.0)

 

Persistent Seropositivity

2 (4.4)

18 (8.2)

3 (5.3)

16 (7.9)

5 (7.7)

14 (7.1)

2 (3.9)

18 (8.4)

2 (3.4)

14 (7.4)

3 (7.7)

14 (6.9)

  1. *Serological status was categorized into three groups as followed: 1) Always seronegative, MFI value stayed < 200 with each visit; 2) Seroconversion, defined by two conditions: (i) an MFI value < 200 in the first and > 200 in the second sample, and (ii) at least a twofold increase of the previous serum value; and lastly 3) Persistent seropositivity, MFI value stayed > 200 in all follow-up visits. Significant results are bolded
Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us